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TSH Receptor and Thyroid-Specific Gene Expression
in Human Skin
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Massimo Teson1, Severino Persechino4, Giovanna Zambruno1, Salvatore Ulisse2, Teresa Odorisio1
and Massimino D’Armiento2
Experimental evidence suggests that in autoimmune thyroid diseases (AITDs) the skin is a target of
autoantibodies against thyroid-specific antigens; however, the role of these autoantibodies in skin alterations
remains unclear. To gain insight into the function of nominally thyroid-specific genes in skin, we analyzed the
expression of thyroid-stimulating hormone–receptor (TSH-R), thyroglobulin (Tg), sodium iodide symporter
(NIS), and thyroperoxidase (TPO) genes in normal human skin biopsies and cultured primary keratinocytes and
dermal fibroblasts. The results revealed the presence of all the transcripts in skin biopsies. However, in
keratinocytes and fibroblasts, only TSH-R messenger RNA was always detected. Western blot and
immunohistochemical analyses of skin specimens confirmed the presence of TSH-R protein in keratinocytes
and fibroblasts. Moreover, TSH treatment induced the proliferation of cultured keratinocytes and fibroblasts
and increased keratinocyte intracellular cAMP. Finally, affinity-purified IgGs from serum of patients affected by
Graves’ disease, but not by chronic lymphocytic thyroiditis, stimulated cAMP accumulation in cultured
keratinocytes, as well as their proliferation. In conclusion, the expression of thyroid-specific genes in cultured
keratinocytes and fibroblasts and the mitogenic effects of TSH and IgGs on these cells support the concept that
autoantibodies against thyroid-specific antigens may contribute to cutaneous symptoms in AITDs.
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INTRODUCTION
Autoimmune thyroid diseases (AITDs) are the most common
organ-specific autoimmune diseases, affecting about 5% of the
population. They comprise several pathological conditions, the
most common being Graves’ disease (GD) and chronic
lymphocytic thyroiditis (CLT) (Stassi and De Maria, 2002;
Weetman, 2003; Jacobson and Tomer, 2007). Patients affected
by AITDs present cellular and humoral immune responses
aberrantly directed against the thyroid. Both GD and CLT are
characterized by the infiltration of the thyroid gland by B and T
lymphocytes and by the production of autoantibodies against
thyroid-specific antigens such as thyroglobulin (Tg), thyroper-
oxidase (TPO), and thyroid-stimulating hormone receptor (TSH-
R). In patients affected by GD, the presence of autoantibodies
stimulating the TSH-R is responsible for the clinical manifesta-
tions of hyperthyroidism, whereas in patients affected by CTL,
the inflammatory infiltrate progressively replaces normal
parenchyma, resulting in thyrocyte depletion through apoptosis
and leading to hypothyroidism and ultimately to gland fibrosis
(Stassi and De Maria, 2002; Weetman, 2003).
Skin development and functions are known to be regulated
by thyroid hormones, and alterations in skin architecture and
homeostasis subsequent to thyroid gland dysfunctions have
been documented (Leonhardt and Heymann, 2002; Burman
and McKinley-Grant, 2006). In particular, thyroid hormones
have been shown to affect fetal epidermal differentiation,
barrier formation, hair growth, sebum production, wound
healing, epidermal oxygen consumption, keratinocyte prolif-
eration, and keratin gene expression (Hanley et al., 1996;
Tomic´-Canic´ et al., 1996; Ko¨mu¨ves et al., 1998; Slominski
and Wortsman, 2000; Leonhardt and Heymann, 2002; Radoja
et al., 2004; Safer et al., 2004). In accordance with these
findings, thyroid hormone receptor expression has been
shown to occur in different skin cell types, including
keratinocytes, dermal fibroblasts, and sebaceous gland cells.
The activity of both type II and type III thyroid hormone
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deiodinases, the enzymes responsible for thyroid hormone
metabolism, has also been detected in human skin (Refetoff
et al., 1972; Huang et al., 1985; Billoni et al., 2000; Torma
et al., 2000; Dentice et al., 2007).
Patients affected by hypothyroidism are characterized by
generalized myxedema—the original term for hypothyroidism
(Horsley, 1885)—with cool, dry, and pale skin. In hyperthyr-
oidism, by contrast, the skin is warm and smooth, and a
generalized hyperhidrosis may be present (Leonhardt and
Heymann, 2002). The dermatological manifestations of hyper-
or hypothyroidism are thought to be consequent to alterations
of general metabolism (for example, a reduced core body
temperature and the resulting cutaneous vasoconstriction are
responsible for the cool skin observed in hypothyroidism) and
thyroid hormone action on the various skin cell types
(Leonhardt and Heymann, 2002; Burman and McKinley-
Grant, 2006). In patients affected by AITDs, however, not all
skin alterations may be explained exclusively by the variations
in circulating thyroid hormones (Ai et al., 2003; Burman and
McKinley-Grant, 2006). For example, pretibial myxedema,
which occurs in approximately 4–5% of patients affected by
GD, is observed in both hyper- and euthyroid patients.
Although the pathogenesis of pretibial myxedema remains to
be defined, the identification of TSH-R transcripts in fibroblasts
and the ability of both TSH and TSH-R antibodies to bind
fibroblasts have led to the hypothesis that pretibial fibroblasts
may be stimulated by thyroid autoantibodies, resulting in an
excessive production of glycosaminoglycans (Wu et al., 1996;
Rapaport et al., 2000; Leonhardt and Heymann, 2002). The
presence of specific TSH-R transcripts and other nominally
thyroid-specific genes, such as the sodium iodide symporter
(NIS), a transmembrane glycoprotein responsible in thyrocytes
for the accumulation of iodide required for thyroid hormone
biosynthesis, and Tg, has also been reported, not only in
human dermal fibroblasts but also in keratinocytes, melano-
cytes, and melanoma cells (Slominski et al., 2002). Moreover,
very recently, TSH-R messenger RNA (mRNA) and protein
were also detected in human scalp hair follicles, which show
differential gene expression after TSH treatment (Bodo´ et al.,
2009). Together, these observations suggest that in the course
of AITDs the functions of the different skin cell types may be
affected not only by variation in thyroid hormone levels but
also by the presence of thyroid-specific autoantibodies.
In this study, to gain more insight into the role of thyroid-
specific molecules in human skin, we first analyzed the
expression of TSH-R, Tg, NIS, and TPO in normal human skin
biopsies and primary cultures of keratinocytes and dermal
fibroblasts. We then evaluated whether TSH and IgGs
purified from the serum of patients affected by AITDs could
exert biological effects on cultured primary human keratino-
cytes and fibroblasts.
RESULTS
Messenger RNA level of thyroid-specific genes in human skin
samples from healthy individuals and cultured primary
keratinocytes and fibroblasts
We initially analyzed by means of RT-PCR the expression
of the TSH-R, Tg, TPO, and NIS on total RNA extracted
from three different human skin biopsies from healthy
individuals. The presence of specific amplicons of the correct
size (Figure 1a) and sequence (data not shown) could be
demonstrated in all three skin specimens. Real-time PCR
quantitative analysis demonstrated that the expression of the
various thyroid-specific genes was significantly lower than
that observed in a pool of total RNA extracted from
three normal human thyroid biopsies (Figure 1b), being
0.0020±0.0006 (Po0.01) for TSH-R mRNA, 0.0069±
0.0001 (Po0.01) for TPO mRNA, 0.0016±0.0010
(Po0.01) for Tg mRNA, and 0.0017±0.0015 (Po0.01) for
NIS mRNA.
The expression of the four genes was further analyzed in
five primary cultures of normal human keratinocytes and
dermal fibroblasts and compared with that observed in a
normal strain of human thyrocytes in culture (HTU5). TSH-R
transcripts were detected in all keratinocytes and dermal
fibroblasts analyzed (Figure 1c), being 0.033±0.013
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Figure 1. Quantitative RT-PCR analysis for NIS, Tg, TPO and TSH-R in skin
and different strains of keratinocytes and fibroblasts. Panels (a) and (c) show
representative agarose gel electrophoresis of the amplified products.
Panels (b) and (d) depict the mRNA levels of the genes in whole human skin
and in keratinocytes and fibroblasts compared with those in normal thyroid
tissue or human thyrocytes, respectively. T, thyrocytes; K, keratinocytes;
Fb, fibroblasts. *Po0.01.
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(Po0.001)-fold and 0.030±0.011-fold, respectively, of that
observed in human thyrocytes (Figure 1d). Specific NIS, Tg,
and TPO mRNAs could also be detected in four of five strains
of cultured keratinocytes. In particular, NIS mRNA levels
did not significantly differ from those observed in human
thyrocytes (1.13±0.76), whereas those of TPO and Tg were,
respectively, 0.012±0.008 (Po0.001)- and 0.003±0.002
(Po0.001)-fold the level detected in thyrocytes. On the
other hand, NIS and TPO transcripts could not be
detected in dermal fibroblasts, whereas Tg mRNA was
expressed in three out of five primary cultures of fibroblasts,
being 0.0013±0.0015-fold of that present in thyrocytes
(Figure 1c and d).
TSH-R protein in human skin samples from healthy individuals
and cultured primary keratinocytes and fibroblasts
We next investigated the expression of the TSH-R at the
protein level by western blot and immunohistochemistry in
normal human skin biopsies, cultured keratinocytes, and
dermal fibroblasts. The ability of the TSH-R antibody to
specifically recognize the TSH-R protein was at first
evaluated. To this end, western blot experiments were carried
out on thyroid tissue extracts under reducing and nonredu-
cing conditions. As expected, in reducing conditions, only
one immunoreactive band of 53 kDa, corresponding to the a
subunit of the TSH-R (Loosfelt et al., 1992), was observed,
whereas in nonreducing conditions, an immunoreactive band
of approximately 120 kDa, corresponding to the holorecep-
tor, was seen (Supplementary Figure S1, panel A). Western
blot conducted in reducing conditions, with extracts from
thyroid tissue, human skin samples, and cultured keratino-
cytes and fibroblasts, showed an immunoreactive band of
53 kDa in all the analyzed tissues and cell type samples
(Figure 2a). However, the filter exposure times required to
visualize a band were longer for skin and cultured cells
(20–30 min) with respect to thyroid tissue (1–2 min).
Immunohistochemistry experiments were carried out on
both paraffin-embedded and frozen skin tissue sections from
healthy donors. Thyroid tissue was also analyzed as control.
As expected, TSH-R expression was confined to epithelial
cells in the thyroid gland (Figure 2b). The immunoreactivity
was predominantly cytoplasmic in paraffin-embedded sec-
tions, whereas it showed a basolateral expression pattern in
most cells in cryosections (Supplementary Figure S1, panel
B). Results obtained from skin specimens confirmed TSH-R
expression in epidermis and dermal cells on both paraffin-
embedded and frozen sections (Figure 2b and c). Keratino-
cyte staining was evident on all cell layers and appeared
stronger in differentiated cells. To confirm that labeled cells
in the dermis were fibroblasts, immunohistochemistry was
carried out on serial frozen tissue sections using the TSH-R
antibody and an antibody against prolyl-4-hydroxylase, a
fibroblast-specific marker (Esterre et al., 1992). The results
showed that several of the TSH-R-positive cells in the
dermis were also stained with the anti-prolyl 4-hydroxylase
(Figure 2c). Double immunofluorescence with the same
antibodies, both monoclonal, was also performed. Staining
given by single immunofluorescence was comparable to that
observed by immunohistochemistry for both antibodies;
however, when the same section was treated with anti-
TSH-R and anti-prolyl-4-hydroxylase, satisfactory results
could not be obtained because of high background (data
not shown).
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Figure 2. TSH receptor (TSH-R) expression in human skin and primary
culture of keratinocytes and fibroblasts. (a) Western blot for detection of
TSH-R a subunit in thyroid, skin, and cultured keratinocyte (Ker) and
fibroblast (Fb) protein extracts. Note that the exposure times of the filters
differed, being longer for skin tissue and cultured cells with respect to thyroid
tissues. (b) Immunohistochemistry analysis of TSH-R on human thyroid tissue,
used as positive control, and on healthy human skin sections.
Immunoreactivity is evident in the follicular cells of the thyroid and in the
epidermis and sparse cells in the dermis (arrows) in skin specimens. Negative
controls (NC) were obtained by omitting the primary antibody. (c)
Immunohistochemistry on serial frozen tissue sections using the TSH-R
antibody and the antibody against prolyl 4-hydroxylase, a fibroblast marker.
Arrows indicate dermal cells that are stained with both antibodies.
Immunohistochemistry data reported are representative of one
out of three normal human skin samples obtained from healthy donors.
Bars ¼ 30 mm.
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Analysis of TSH-R activity in cultured keratinocytes and
fibroblasts
We then analyzed keratinocyte and fibroblast proliferation
following treatment of cultured cells with TSH. Because
thyroid hormones have previously been shown to increase
keratinocyte and fibroblast proliferation (Safer et al., 2001),
triiodothyronine (T3) (10 nM, for 72 h) was used in these
experiments as positive control. As reported in Figure 3a, T3
treatment stimulated both keratinocyte and fibroblast BrdU
incorporation 1.45±0.05-fold (Po0.01) and 1.58±0.03-
fold, respectively (Po0.01). Similarly, TSH treatment
(10 mUI ml1 for 72 h) induced a significant increase in BrdU
incorporation in both cell types 1.42±0.05-fold (Po0.01)
and 1.53±0.06-fold, respectively (Po0.01). Treatment with
both TSH (10 mUI ml1) and T3 (10 nM) for 72 h did not result
in additive or synergistic effects (data not shown).
The ability of TSH (10 mUI ml1, for 2 h) to cause
intracellular cAMP accumulation in cultured keratinocytes
and dermal fibroblasts was also investigated. The results
demonstrated that TSH stimulates intracellular cAMP
1.59±0.18-fold (Po0.05) in keratinocytes, but not in
fibroblasts (Figure 3b).
Because TSH represents the main regulator of Tg, TPO,
NIS, and TSH-R expression in thyrocytes, we analyzed its
effect on the thyroid-specific gene expression in keratinocyte
and fibroblast cell cultures. The results, reported in Supple-
mentary Table S2, demonstrated the failure of TSH
(10 mUI ml1, for 24 h) to affect Tg, TPO, NIS, and TSH-R
mRNA levels in both cell types. Moreover, as assessed by a
highly sensitive Tg luminescence immunoassay, no Tg
protein in either cell supernatant could be detected in basal
or TSH-stimulated (10 mUI ml1, for 24 h) conditions,
whereas an increase of about 20-fold in Tg secretion was
observed following TSH treatment of HTU5 cells used as
positive control (data not shown).
Analysis of cultured keratinocyte functions after treatment with
IgGs purified from serum of patients affected by autoimmune
thyroid diseases
We next sought to verify whether IgGs purified from the
serum of patients (n¼ 3, see Table 1) affected by GD could
affect BrdU incorporation and cAMP accumulation in
primary cultures of human keratinocytes. As controls,
cultured keratinocytes were treated with IgGs purified from
serum of healthy individuals (n¼ 3) or from patients affected
by CLT (n¼4), with a high level of circulating anti-Tg and/or
anti-TPO autoantibodies (Table 1). As reported in Figure 4a,
affinity-purified IgGs (1 mg ml1) from the serum of patients
affected by GD, but not from patients with CLT, significantly
stimulated proliferation with respect to IgGs purified from the
serum of healthy individuals (1.48±0.06 fold, Po0.05). In
keeping with this finding, the analysis of cAMP accumulation
indicated that only purified IgGs from patients affected by GD
were able to induce a significant increase in intracellular
cAMP (1.88±0.20, Po0.01), compared with those from
healthy controls (Figure 4b).
DISCUSSION
The evidence that thyroid dysfunctions often associate with
skin alterations has been correlated with the capacity of
thyroid hormones to directly affect skin cell activity by
binding to their cognate nuclear receptors. The possibility
that in AITDs circulating autoantibodies directed against
specific thyroid molecules also contribute to skin dysfunc-
tions has been put forward (Slominski et al., 2002). Our
results show that keratinocytes and dermal fibroblasts from
biopsies of normal individuals express functional TSH-R. In
addition, they provide evidence that circulating TSH-R
autoantibodies may affect skin cell functions, supporting the
concept that autoantibodies against thyroid-specific antigens
may contribute to cutaneous symptoms in AITD.
To acquire insight into the possible role of thyroid-specific
molecules in the skin, we first analyzed the expression of
TSH-R, Tg, TPO, and NIS genes in normal human skin
biopsies and primary keratinocyte and fibroblast cultures. A
previous study by Slominski et al. (2002) described TSH-R
mRNA expression in skin biopsies, in epidermal and hair
follicle keratinocytes and melanocytes, in dermal and hair
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Figure 3. Effects of TSH and T3 treatment on keratinocyte and fibroblast
proliferation and cAMP accumulation. (a) To evaluate the effects of TSH
(10 mUI ml1) and T3 (10 mM) on keratinocyte and fibroblast proliferation,
primary cultures were plated in 96 wells and treated for 72 h in the presence
or absence of the two hormones. BrdU was added to the cells 16 h before the
end of incubation time, and the incorporated BrdU was measured by ELISA.
*Po0.01. (b) Intracellular cAMP levels measured in basal and TSH-stimulated
(10 mUI ml1 for 2 h) keratinocytes and fibroblasts by ELISA. *Po0.05.
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follicle fibroblasts, and in melanoma cell lines. Tg and NIS
mRNAs, but not TPO mRNA, were also found to be expressed
in the keratinocyte cell line HaCaT and melanoma cell lines.
Our study confirms and further characterizes the expression
of all four thyroid-specific genes in skin biopsies from healthy
individuals and in a panel of primary keratinocyte and
fibroblast cultures at low passage. However, Bodo´ et al.
(2009) recently reported the expression of TSH-R and Tg in
human hair follicles and that such expression was limited to
the mesenchymal cells of the pilosebaceous unit, whereas it
was not observed in interfollicular dermal fibroblasts and
keratinocytes. Different skin locations (scalp versus buttock,
shoulder, calf, or thigh analyzed here) and/or different
reagents used (that is, anti-TSH-R antibodies) may give an
explanation for such discrepant data. In the present study, of
the four genes analyzed, only TSH-R mRNA was always
found in all the primary cultures analyzed. To explain the
diverse expression of the other genes in the cell strains
analyzed, we looked at whether it could be related to
differences in the body district or in the donor’s age, but no
correlation could be found. Alternatively, their differential
expression could be ascribed to the different activities of the
transcription factor(s) regulating the expression of the thyroid-
specific genes in the analyzed primary cell cultures and skin
cell types. In thyrocytes, the expression of thyroid-specific
genes is sustained by the combined action of at least three
transcription factors: thyroid transcription factor-1, forkhead/
winged-helix domain transcription factor FoxE1, and the
paired box 8 (Pax8) (Damante et al., 2001). Even if the
expression and function of these transcription factors in
human skin remain to be fully investigated, the expression of
thyroid transcription factor-1 in rat keratinocytes and in
human hair follicle and that of FOXE1 in human epidermis
have been described (Suzuki et al., 1998; Eichberger et al.,
2004; Bodo´ et al., 2009). Further investigation in this
direction might help to clarify the significance of the
differential expression of the Tg, NIS, and TPO genes in
human skin.
The results of quantitative RT-PCR showed that, with the
exception of NIS mRNA in keratinocytes, all the thyroid-
specific gene mRNAs are present in the skin or in cultured
keratinocytes and fibroblasts at levels much lower than those
observed in, respectively, human thyroid tissues or thyrocytes
in culture. This may suggest the presence of an illegitimate
transcription of thyroid-specific genes in skin cells (Chelly
et al., 1989). However, we showed herein by immunohis-
tochemistry and western blot experiments that the TSH-R
gene, at least, is expressed at the protein level in skin biopsies
and cultured keratinocytes and fibroblasts. This strongly
argues against an illegitimate transcription and raises the
question of the physiological role of TSH-R in skin functions.
In this regard, a previous report demonstrated the ability of
TSH-R to mediate TSH and anti-TSH-R antibody stimulation
of cAMP in the immortalized human keratinocyte cell line
HaCaT (Slominski et al., 2002). In the present study, we could
confirm these observations with normal keratinocytes and
Table 1. Female subjects selected for the analysis of the effect of purified IgG on keratinocyte functions
Age TSH (mU l1) FT4 (pgml1) Ab-Tg (Uml1) Ab-TPO (Uml1) Ab-TSH-R (UI l1) Diagnosis
33 2.13 12.3 o60 o60 o1 Healthy
33 1.81 14.8 o60 o60 o1 Healthy
49 1.83 12.9 o60 o60 o1 Healthy
55 6.79 10.5 2,507 4,514 o1 Chronic lymphocytic thyroiditis
66 15.21 12.1 1,310 11,690 o1 Chronic lymphocytic thyroiditis
36 1.62 11.2 430 1,380 o1 Chronic lymphocytic thyroiditis
38 2.39 10.1 3,855 3,238 o1 Chronic lymphocytic thyroiditis
38 o0.01 32.7 o60 195 11.76 Graves’ disease
32 o0.01 24.6 107 631 5.46 Graves’ disease
45 3.02 8.2 157 1,102 8.84 Graves’ disease
Normal range values: TSH: 0.4–4 mU l1; FT4: 8–19 pg ml1; Ab-Tg: o60 U ml1; Ab-TPO: o60 U ml1 Ab-TSH-R: o1 UI l1.
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Figure 4. Proliferation and cAMP levels in human keratinocytes following
treatment with IgGs. The effects of IgGs purified from serum of healthy
females (n¼ 3) or from that of female patients affected by chronic
lymphocytic thyroiditis (n¼4) or Graves’ disease (n¼ 3) on keratinocyte
proliferation (a) or intracellular cAMP accumulation (b). *Po0.05, **Po0.01.
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demonstrated the ability of TSH to induce proliferation of
keratinocytes and dermal fibroblasts, which, to our knowl-
edge, has not previously been reported. Moreover, we
showed that IgGs purified from the serum of patients affected
by GD stimulate human keratinocyte proliferation. In
keratinocytes, this effect is associated with the accumulation
of intracellular cAMP, although we could not detect any
cAMP increase after TSH treatment in dermal fibroblasts. The
lack of a cAMP rise in fibroblasts may suggest the presence in
this cell type of different intracellular signaling pathway(s)
activated by TSH. In fact, TSH has been documented to
induce, in addition to cAMP, the protein kinase C pathway in
thyroid cells. Ellerhorst et al., 2006 demonstrated the ability
of TSH to stimulate the proliferation of two melanoma
cell lines, WM793 and MeWo. In this study, TSH was
shown to stimulate cAMP accumulation in WM793 cells, but
not in MeWo cells, and to activate the MAPK pathway in both
cell lines.
TSH represents the main regulator of thyroid-specific gene
expression in thyrocytes. The finding of functional TSH-R in
human keratinocytes and fibroblasts led us to investigate the
effects of TSH treatment on keratinocyte and fibroblast Tg,
TPO, NIS, and TSH-R mRNA levels. The results failed to show
any effect of TSH on the expression of these genes. Similar
observations were made by Sellitti et al. (2000a, b), who
reported the expression of functional TSH-R and Tg in a
primary culture of human kidney cells and the lack of effect
of either TSH or cAMP analog on Tg expression. More
recently, however, Bodo´ et al. (2009) reported the ability of
TSH to induce extracellular cAMP accumulation and the Tg
mRNA level in scalp hair follicles in organ culture (Bodo´
et al., 2009).
Collectively, the above-reported experimental evidence
indicates a role for TSH in human skin as already described in
other extrathyroidal tissues in which the presence of
functional TSH-R has been documented (U¨mit Bag˘riac¸ik
and Klein, 2000; Sellitti et al., 2000a, b; Busuttil and
Frauman, 2001; Slominski et al., 2002; Ellerhorst et al.,
2006). The present data on the stimulation of proliferation of
keratinocytes and dermal fibroblasts, along with those
previously described on melanoma and kidney cells, suggest
a mitogenic role for TSH in extrathyroidal target tissues
(Sellitti et al., 2000a; Ellerhorst et al., 2006). This may have
several implications, such as for the reported higher
prevalence of hypothyroidism among melanoma patients
with respect to the general population (Ellerhorst et al., 2006).
Moreover, our findings and those of Slominski et al. (2002)
suggest that, in patients affected by GD, circulating anti-
TSH-R autoantibodies may contribute, together with
abnormal thyroid hormone levels, toward inducing skin altera-
tions and also may make it reasonable to speculate that some
forms of GD may result from autoimmune responses directed
primarily against cutaneous TSH-R (Slominski et al., 2002).
In this context, retrospective or prospective epidemiologi-
cal studies aimed at evaluating the incidence of GD in
patients who have a skin lesion (that is, skin inflammation,
abnormal skin UV exposure, or medical exposure to
radiation) may help to provide, although indirectly, evidence
for the role of cutaneous TSH-R in the pathogenesis of GD.
On the other hand, the ability of TSH to promote skin cell
proliferation presents the possibility that this factor may have
a role in enhancing cell response in those processes in which
proliferation is required, such as wound healing.
In the human thyroid, TSH represents the main driver for
both proliferation and differentiation of thyrocytes. The
observation that TSH-R immunohistochemical staining is
more intense in the epidermal upper layers suggests a
possible role for the TSH/TSH-R axis in keratinocyte
differentiation as well. However, whether TSH may affect,
in addition to proliferation, keratinocyte and dermal fibro-
blast differentiation remains to be investigated.
With regard to the expression of the other nominally
thyroid-specific genes, Tg, NIS, and TPO, their role in
human skin, as in other extrathyroidal tissues, remains to be
clarified (Sellitti et al., 2000a; Sellitti et al., 2000b; U¨mit
Bag˘riac¸ik and Klein, 2000; Busuttil and Frauman, 2001;
Slominski et al., 2002).
In conclusion, our data confirm the expression of thyroid-
specific genes in human skin and show a mitogenic role for
TSH and TSH-R autoantibodies in keratinocytes and fibro-
blasts. These findings suggest a role for TSH in the regulation
of skin cell functions and indicate that circulating auto-
antibodies may contribute to skin alterations in the course of
autoimmune thyroid diseases.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium, Ham’s F12 growth medium,
F10 medium, L-glutamine, trypsin/EDTA, penicillin/streptomycin,
Trizol reagent, oligo(dT)1218 primer 0.5 mgml
1, and M-MLV reverse
transcriptase 200 U ml1 were purchased from Invitrogen (Carlsbad,
CA). BSA, trizma base, glycine, adenine, insulin, hydrocortisone,
triiodothyronine, cholera toxin, and the polyclonal anti-actin anti-
body (AA20-33) were obtained from Sigma Chemical (St Louis, MO).
Fetal bovine serum was purchased from HyClone (South Logan, UT).
Precision Protein Standard, the Bradford protein assay kit, and
electrophoresis reagents were obtained from Bio-Rad Laboratories
(Hercules, CA). The Perfectprep Gel Cleanup Kit was obtained from
Eppendorf (Hamburg, Germany). Microconcentrators Centricon 10
was from Millipore (Bedford, MA). Diaminobenzidine substrate
system was from Dako Cytomation GmbH (Hamburg, Germany).
The mouse monoclonal antibody raised against peptide 147–228 of
the human TSH-R (Clone A9) and the mouse monoclonal antibody
against prolyl 4-hydroxylase (5B5) were from GeneTex (San Antonio,
TX). Anti-mouse and anti-rabbit peroxidase-conjugated antibodies
and SuperSignals chemiluminescent substrate were from Pierce
(Rockford, IL). Anti-mouse biotinylated and FITC- and TRITC-labeled
antibodies and the Vectastain Elite ABC kit were from Vector
Laboratories (Burlingame, CA). Protein A Sepharose CL-4B was
obtained from Amersham Biosciences (Uppsala, Sweden). The BrdU
cell proliferation kit and the FastStart DNA MasterPLUS SYBR Green I
kit were from Roche Applied Sciences (Mannheim, Germany). The
kit Parameter cAMP was from R&D System Europe (Abingdon, UK).
Luminescence immune-assay kits for the determination of serum Tg,
TSH, free T4, and autoantibodies against Tg, TPO, and TSH-R were
purchased from Brahms (Berlin, Germany).
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Cell cultures and tissue samples
The normal strain of HTU5 was cultured as previously described
(Curcio et al., 1994). Of the five strains of normal human
fibroblasts and keratinocytes, two were established from foreskin
(samples 2 and 4), one from buttock (sample 1), one from
shoulder (sample 3), and one from groin (sample 5) skin
biopsies of five healthy individuals. Fibroblasts were grown in
F10 medium supplemented with 10% fetal calf serum, 1% gluta-
mine, and 1% penicillin/streptomycin, and keratinocytes
were cultured on a feeder layer of lethally irradiated 3T3-J2
murine fibroblasts (a gift from Howard Green, Harvard Medical
School, Boston, MA) in Dulbecco’s modified Eagle’s medium
and Ham’s F12 (3:1 mixture) containing FCS (10%), insulin
(5mg ml1), transferrin (5mg ml1), adenine (0.18 mM), hydro-
cortisone (0.4 mg ml1), cholera toxin (0.1 nM), T3 (2 nM), EGF
(10 ng ml1), glutamine (4 mM), and penicillin–streptomycin
(50 IU ml1), as previously described (Zambruno et al., 1995). All
the experiments on the primary cell cultures were carried out at
cellular passages 2 to 4.
Paraffin-embedded skin tissue samples were obtained from
surgical specimens of healthy female individuals confirmed as
having normal thyroid function and not taking relevant medication
at the time of harvest. One skin biopsy was from the buttock,
one from the shoulder, and one from the calf. Frozen skin samples
were from healthy female individuals undergoing plastic surgery
(two biopsies were from the abdomen and one from the breast).
Normal thyroid tissue fragments were obtained from patients
subjected to thyroidectomy for benign follicular adenoma. This
study was approved by the Ethics Committee of the Istituto
Dermopatico dell’Immacolata. The Declaration of Helsinki proto-
cols were followed, and patients gave their written informed
consent.
Messenger RNA extraction and analysis
Tissue samples were homogenized in Trizol reagent, and total
cellular RNA was extracted from tissue samples or cultured cells by
the acid guanidinium thiocyanate–phenol–chloroform method
(Chomczynski and Sacchi, 1987). Five micrograms of total
RNA was reverse-transcribed, and cDNAs were used as a template
for the subsequent quantitative PCR amplifications of the TSH-R, Tg,
NIS, TPO, and b2-microglobulin as internal control, using specific
primers (Supplementary Table S1). Controls for DNA contamination
were obtained by omitting the reverse transcriptase or RNA during
reverse transcription. Real-time PCR assay was carried out on a
LightCycler instrument (Roche Diagnostics, Monza, Italy) using the
FastStart DNA Master SYBR Green I kit (Roche Diagnostics). Samples
were processed in triplicate, and PCR-grade water was used as
negative control. The PCR products were analyzed on a 2% agarose
gel. To determine the specificities of amplified cDNAs, they were
recovered from the gel and sequenced using the ABI Prism 377 DNA
sequencer (PerkinElmer, Boston, MA). The crossing points (Cp) for
each reaction were determined, and data were calculated using the
DDCp method and the LightCycler Relative Quantification software,
version 1.0 (Roche Diagnostics). The expression of thyroid-specific
genes in keratinocytes and fibroblasts or in whole skin was
normalized against the expression found in the normal strain of
HTU5 or in normal human thyroid tissue, respectively, and reported
as fold of variation.
Western blot
Normal skin and thyroid tissues were homogenized in RIPA buffer
(50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% sodium deoxycholate,
150 mM sodium chloride, 1 mM EDTA, 1 mM sodium fluoride, 1 mM
AEBSF, 10 mg ml1 aprotinin, 10mg ml1 leupeptin, 1 mM sodium
orthovanadate, 10 mM sodium pyrophosphate in ddH2O), sonicated,
and centrifuged at 10,000 r.p.m. for 10 min. The supernatants were
then recovered, and protein concentrations were determined by the
Bradford assay. Fifty micrograms of extracts was supplemented with
Laemmli buffer (120 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
0.01% bromophenol blue) with or without b-mercaptoethanol (1%),
electrophoresed on a 12.5% polyacrylamide gel, and transferred
onto nitrocellulose membranes using the Bio-Rad Mini Trans-Blot
Cell system. The membranes were then washed with TBST (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and saturated
with 5% low-fat milk in TBST for 2 h at room temperature.
Incubations with primary antibodies against the TSH-R (1:5,000) or
actin (1:1,000) were carried out in TBST containing 2% low-fat milk
at 4 1C overnight. The membranes were then washed and incubated
with anti-mouse (1:1,000) horseradish peroxidase-conjugated sec-
ondary antibodies in TBST plus 2% low-fat milk for 2 h at room
temperature. After several washes with TBST, western blots were
revealed using the chemiluminescence Super Signal kit.
BrdU incorporation assay
Keratinocytes and fibroblasts were plated in 96-well plates at a
density of 2 104 cells per well in a medium without serum, EGF,
T3, and cholera toxin and in the presence of 0.1% bovine serum
albumin (BSA). On the following day, the cells were washed and
incubated in triplicate with TSH (10 mUI ml1), T3 (10 nM), or
medium alone (control) for 72 h. In separate experiments, the cells
were incubated for 72 h with immunoglobulins purified from the
blood serum of control subjects or from patients affected by CLT or
GD. BrdU was added to the cells 16 h before the end of the
incubation time, and its incorporation was analyzed using the cell
proliferation kit according to the manufacturer’s instructions.
cAMP assay
Keratinocytes and fibroblasts were cultured in 96-well plates for
4 days in medium without serum, EGF, T3, and cholera toxin and in
the presence of 0.1% BSA. The cells were then washed and
incubated in triplicate with TSH (10 mUI ml1) or medium alone
(control) for 2 h. In different experiments, the cells were incubated
for 2 h with immunoglobulins purified from the blood serum of
control subjects or patients affected by CLT or GD. At the end of the
incubation time, intracellular cAMP levels were measured with the
Parameter cAMP kit according to the manufacturer’s instructions.
Thyroglobulin assay
Normal human keratinocytes and dermal fibroblasts were cultured
for 4 days in medium without serum, EGF, T3, or cholera toxin and in
the presence of 0.1% BSA. Cells were then cultured in the absence
or presence of TSH (10 mUI ml1) for 24 h. At the end of the
incubation, the conditioned media were collected and Tg was
measured by a highly sensitive luminescence immune assay as
previously described (Morgenthaler et al., 2002). Conditioned media
from normal human thyrocytes cultured in the absence or presence
of TSH (10 mUI ml1) were used as control.
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Immunohistochemical analysis
Four-micrometer-thick paraformaldehyde-fixed and paraffin-em-
bedded sections of normal human thyroid and skin were depar-
affinized, rehydrated, and treated for 20 min with 0.3% H2O2 in
phosphate-buffered saline (PBS). Sections were preincubated with
3% BSA in PBS for 1 h at room temperature and then incubated with
the primary antibody raised against human TSH-R (1:500) overnight
at 4 1C. The sections were then washed and incubated with the
secondary anti-mouse biotinylated antibody (1:150) in PBS for 1 h at
room temperature, washed again, and incubated for 1 h with an
avidin–biotin–peroxidase complex (Vectastain Elite ABC kit). For the
analysis of frozen tissues, 3-mm-thick sections from thyroid and skin
specimens were used, and samples were fixed for 10 min in cold
acetone. For TSH-R expression analysis, the method described above
was followed using the primary antibody diluted 1:250. Prolyl
4-hydroxylase was detected by incubating with the primary antibody
(1:50) for 1 h at room temperature, followed by incubation with the
biotinylated anti-mouse antibody (1:200) for 30 min at room
temperature. Immunoreactivity was visualized by a peroxidase
reaction using diaminobenzidine tetrahydrochloride in H2O2 and
counterstaining with hematoxylin. For immunofluorescence analy-
sis, an FITC-conjugated secondary antibody was used to detect TSH-
R and a TRITC-conjugated one for prolyl 4-hydroxylase. When used
together on the same specimen, the primary antibodies were
preincubated with an excess (molar ratio) of the secondary antibody,
and the complexes were simultaneously added to the tissue sample.
Negative controls were obtained by omitting the primary antibody or
by incubating specimen sections with nonspecific IgGs instead of
with primary antibody.
Purification of immunoglobulins from blood serum
Blood sera were obtained from three female patients affected by GD,
from three female patients affected by CLT, and from four healthy
females enrolled at the Thyroid Clinic of the Policlinico Umberto I of
Rome. All patients gave their informed consent. Serum determina-
tion of TSH, free T4 (FT4), and autoantibodies against Tg, TPO, and
TSH-R was carried out using commercially available kits according
to the manufacturer’s instructions. IgGs were purified from 0.5 ml of
blood serum samples by affinity chromatography using Protein A
Sepharose CL-4B columns in accordance with the manufacturer’s
instructions (Miller and Stone, 1978). Briefly, 0.5 ml of serum was
diluted in PBS and loaded on a column containing approximately
100 mg of PBS-equilibrated Protein A Sepharose. After an overnight
incubation at 4 1C, unbound material was eluted by three washes
with 5 ml of PBS. Bound IgGs were eluted with 2.5 ml of glycine
chloride 100 mM (pH 2.7), collecting 0.5 ml fractions. The collected
IgG fractions were immediately neutralized (pH 7.0) with Tris-base
1 M. The protein concentration of each fraction was estimated using
the Bradford assay and concentrated to 10 mg ml1 using Micro-
concentrators Centricon 10. To verify IgG purification, a small
aliquot of each sample was run on 10% SDS–PAGE. After Coomassie
blue staining, only two bands at about 50 and 30 kDa, corresponding
to the molecular weights of the Ig heavy and light chains,
respectively, were observed (data not shown).
Statistical analysis
Data are expressed as mean±SEM. Statistical significance of
differences was determined using the mean values of replicates of
three independent experiments, each performed at least in triplicate
and evaluated by the two-tailed Student t-test. The differences were
considered to be statistically significant if the P-values were lower
than 0.05.
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